ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining

Chen, Yanli; Tian, Dong; Chen, Xiaoqi; Tang, Zhi; Li, Kuina; Huang, Zhijiong; Fu, Yong; Feng, Yanying; Yang, Zhijun

doi:10.2147/ijgm.s302012

Cited by 6 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, using GSEA, we again confirmed that ARRDC2 was highly and consistently enriched in immune-related signaling pathways. Studies have shown that ARRDC3, an important member of the ARRDC family, was closely related to immunity in epithelial ovarian cancer, which supports our research ( Chen et al, 2021 ). The above enrichment analysis suggested that ARRDC2 may play an oncogenic role in ovarian cancer by influencing immune factors in the tumor microenvironment.…”

Section: Discussionsupporting

confidence: 92%

“…A great many studies have shown that genes in the ARRDC family contributed to the progression of various malignancies such as gastric, cervical and colorectal cancers, and were strongly associated with poor prognosis ( Shen et al, 2018 ; Xiao et al, 2018 ; Takeuchi et al, 2019 ). For instance, ARRDC3, a member of the ARRDC family, served as a biomarker for the diagnosis and prognosis of epithelial ovarian cancer ( Chen et al, 2021 ). From this, it can be boldly speculated that ARRDC2 may likewise act as an oncogene in ovarian cancer and lead to poor prognosis, but its possible oncogenic mechanisms need to be further explored.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

Zhang

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: The abnormal expression of α-arrestin protein family plays a key regulatory role in the occurrence and development of many cancers, including colorectal cancer and cervical cancer, and is inseparable from changes in the tumor immune microenvironment. However, the role of ARRDC2, an important member of this family, in the malignant biological process of ovarian cancer (OC) has not been reported, and its role in the change of the immune microenvironment is also unknown.Methods: In this study, HPA, TCGA, GEO and other databases were used to explore the role of ARRDC2 in the prognosis assessment of ovarian cancer. Then, GO, KEGG analysis and GSEA analysis of the biological processes and cell signaling pathways that ARRDC2 may be involved in activated or inhibited. In addition, the TIMER and TISIDB database were used to conduct in-depth research on the role of ARRDC2 in the change of the immune microenvironment of ovarian cancer. The CMap database explored and screened drugs that may be used for treatment. Through cell transfection, CCK-8, Ki-67 immunofluorescence, wound healing, transwell and clone formation assay, the effect of ARRDC2 knockdown on the malignant biological behavior of OC cells were explored.Results: There were significant differences between OC and ARRDC2 mRNA and protein levels. High ARRDC2 expression level is associated with poor overall survival and can be used as an independent prognostic factor. Interestingly, ARRDC2 expression is positively correlated with B cells, Neutrophils, Dendritic cells and CD8+ T cells, signifying that ARRDC2 may be related to infiltration of immune cells. ARRDC2 and its co-expressed genes are enriched in cell signaling pathways related to the immune system. We explored two possible drugs for the treatment of ovarian cancer. Finally, the results of in vitro experiments indicated that knockdown of ARRDC2 may inhibit malignant phenotypes such as proliferation and migration of OC cells.Conclusion: The differentially expressed ARRDC2 may be a potential prognostic indicator and can be used as a novel biomarker for exploring the immune microenvironment of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

Zhang

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Meanwhile, using GSEA, we again con rmed that ARRDC2 was highly and consistently enriched in immune-related signaling pathways. Studies have shown that ARRDC3, an important member of the ARRDC family, was closely related to immunity in epithelial ovarian cancer, which supports our research (16). The above enrichment analysis suggested that ARRDC2 may play an oncogenic role in ovarian cancer by in uencing immune factors in the tumor microenvironment.…”

Section: Discussionsupporting

confidence: 88%

“…A great many studies have shown that genes in the ARRDC family contributed to the progression of various malignancies such as gastric, cervical and colorectal cancers, and were strongly associated with poor prognosis (13)(14)(15). For instance, ARRDC3, a member of the ARRDC family, served as a biomarker for the diagnosis and prognosis of epithelial ovarian cancer (16). From this, it can be boldly speculated that ARRDC2 may likewise act as an oncogene in ovarian cancer and lead to poor prognosis, but its possible oncogenic mechanisms need to be further explored.…”

Section: Discussionmentioning

confidence: 99%

A Novel Prognostic Biomarker ARRDC2 has Potential to Define Tumor Microenvironment in Ovarian Cancer

M¹,

Y²,

Hou³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: The abnormal expression of α-arrestin protein family plays a key regulatory role in the occurrence and development of many cancers, including colorectal cancer and cervical cancer, and is inseparable from changes in the tumor immune microenvironment. However, the role of ARRDC2, an important member of this family, in the malignant biological process of ovarian cancer (OC) has not been reported, and its role in the change of the immune microenvironment is also unknown.Methods: In this study, HPA, TCGA, GEO and other databases were used to explore the role of ARRDC2 in the diagnosis and prognosis assessment of ovarian cancer. Then, GO, KEGG analysis and GSEA analysis of the biological processes and cell signaling pathways that ARRDC2 may be involved in activated or inhibited. In addition, the TIMER and TISIDB database were used to conduct in-depth research on the role of ARRDC2 in the change of the immune microenvironment of ovarian cancer. Finally, the CMAP database explored and screened drugs that may be used for treatment.Results: There were significant differences between OC and ARRDC2 mRNA and protein levels. High ARRDC2 expression level is associated with poor overall survival and can be used as an independent prognostic factor. Interestingly, ARRDC2 expression is positively correlated with B cells, Neutrophils, Dendritic cells and CD8+ T cells, signifying that ARRDC2 may be related to infiltration of immune cells. ARRDC2 and its co-expressed genes are enriched in cell signaling pathways related to the immune system. Finally, we explored two possible drugs for the treatment of ovarian cancer.Conclusion: The differentially expressed ARRDC2 may be a potential prognostic and diagnostic indicator and can be used as a novel biomarker for exploring the immune microenvironment of ovarian cancer.

show abstract

“…It is speci cally involved in the degradation and regulation of PAR1 via ALIX in triple-negative breast cancer [12]. ARRDC3 also suppresses tumor metastasis in other cancers [35][36][37][38][39]. In the present study, no signi cant results were obtained for p16-positive oropharyngeal cancer specimens.…”

Section: Discussioncontrasting

confidence: 59%

Protease-Activated Receptor 1 (PAR1) Expression Contributes to HPV-Associated Oropharyngeal Cancer Prognosis

Fujita

Fukuda

Sanuki

et al. 2023

Head and Neck Pathol

View full text Add to dashboard Cite

Background: Human papillomavirus (HPV)-associated oropharyngeal cancer occasionally has a poor prognosis, making prognostic risk strati cation crucial. Protease-activated receptor-1 (PAR1) is involved in carcinogenesis and is regulated by alpha-arrestin domain-containing protein 3 (ARRDC3). It is also involved in the tumor microenvironment. We sought to evaluate the predictive ability of PAR1, ARRDC3, and tumorin ltrating lymphocyte (TIL) scores in patients with oropharyngeal, hypopharyngeal, and uterine cervical cancers, serving as comparators for HPV-associated oropharyngeal cancer.Methods: Immunohistochemical analysis of p16, ARRDC3, and PAR1 expression was performed for 79 oropharyngeal, 44 hypopharyngeal, and 42 uterine cervical cancer samples. The TIL scores were assessed and classi ed into the following groups based on invasion: Low: 0 %-10 %, Medium: 20 %-40 %, and high: >50 %. For prognostic analysis, the three groups were evaluated by dividing them into low, medium, and high categories, or alternatively into two groups using the median value as the cutoff.Results: p16 was expressed in 44 (56 %) oropharyngeal, 8 (18 %) hypopharyngeal, and all uterine cervical cancer samples. ARRDC3 was detected in 39 (49 %) oropharyngeal, 25 (57 %) hypopharyngeal, and 23 (55 %) uterine cervical cancer samples. PAR1 was expressed in 45 (57 %) oropharyngeal, 22 (50 %) hypopharyngeal, and 22 (50 %) uterine cervical cancer samples. Patients diagnosed with p16-positive oropharyngeal cancer had a substantially improved prognosis compared to those diagnosed as p16negative cases. Compared to the p16-positive cases, the PAR1-negative cases had a considerably improved prognosis compared to the positive cases (disease-speci c survival [DSS] and -negative cases (disease-free survival [DFS]). Multivariate analysis revealed that ARRDC3-positive cases had an appreciably better DSS prognosis than patients with p16-negative oropharyngeal cancers.PAR1-positive cases among patients with p16-positive oropharyngeal cancer had a poor prognosis. With respect to DFS, patients with PAR1positive and p16-negative oropharyngeal cancer had a 35-fold higher recurrence rate than those with PAR1negative and p16-negative oropharyngeal cancer. Conclusion:Our results suggest that PAR1 expression affects the prognosis and recurrence rate of HPVassociated oropharyngeal cancer.

show abstract

ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining

Cited by 6 publications

References 32 publications

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

A Novel Prognostic Biomarker ARRDC2 has Potential to Define Tumor Microenvironment in Ovarian Cancer

Protease-Activated Receptor 1 (PAR1) Expression Contributes to HPV-Associated Oropharyngeal Cancer Prognosis

Contact Info

Product

Resources

About